LLY

712.3

-0.96%↓

JNJ

152.93

+0.1%↑

ABBV

183.65

+0.55%↑

NVO

66.97

-1.89%↓

UNH

293.62

-2.2%↓

LLY

712.3

-0.96%↓

JNJ

152.93

+0.1%↑

ABBV

183.65

+0.55%↑

NVO

66.97

-1.89%↓

UNH

293.62

-2.2%↓

LLY

712.3

-0.96%↓

JNJ

152.93

+0.1%↑

ABBV

183.65

+0.55%↑

NVO

66.97

-1.89%↓

UNH

293.62

-2.2%↓

LLY

712.3

-0.96%↓

JNJ

152.93

+0.1%↑

ABBV

183.65

+0.55%↑

NVO

66.97

-1.89%↓

UNH

293.62

-2.2%↓

LLY

712.3

-0.96%↓

JNJ

152.93

+0.1%↑

ABBV

183.65

+0.55%↑

NVO

66.97

-1.89%↓

UNH

293.62

-2.2%↓

Search

Roivant Sciences Ltd

Aperta

SettoreSettore sanitario

10.85 -0.73

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

10.78

Massimo

10.97

Metriche Chiave

By Trading Economics

Entrata

212M

25M

Vendite

4.5M

9M

EPS

-0.199

Margine di Profitto

280.018

Dipendenti

908

EBITDA

-52M

-274M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+64.99% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

7.7B

Apertura precedente

11.58

Chiusura precedente

10.85

Notizie sul Sentiment di mercato

By Acuity

50%

50%

174 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Roivant Sciences Ltd Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

22 mag 2025, 23:48 UTC

Azioni calde

Stocks to Watch: Deckers Outdoor, Intuit, Ross Stores, Lightbridge, NuScale Power, Centrus Energy

22 mag 2025, 23:07 UTC

Notizie principali

Fortescue Energy CEO to Resign in Executive Overhaul

22 mag 2025, 23:03 UTC

I principali Market Mover

Nuclear-Industry Stocks Get Boost After Report Says Trump Will Sign Orders to Jumpstart Field

22 mag 2025, 23:59 UTC

Discorsi di Mercato

Gold Edges Higher, Supported by Lingering Worries Over U.S. Deficits -- Market Talk

22 mag 2025, 23:45 UTC

Discorsi di Mercato

Nikkei May Trade in Range as Uncertainty Over Tariffs Continues -- Market Talk

22 mag 2025, 23:45 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

22 mag 2025, 23:23 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

22 mag 2025, 23:23 UTC

Discorsi di Mercato

Fortescue Iron Bridge Delay Disappoints; Executive Changes Welcomed -- Market Talk

22 mag 2025, 23:12 UTC

Notizie principali

Supreme Court Lets Trump Fire Agency Officials, but Moves to Protect Fed -- WSJ

22 mag 2025, 21:54 UTC

Notizie principali

Global Finance Officials Gloss Over Trade Tensions At G-7 Summit -- WSJ

22 mag 2025, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

22 mag 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

22 mag 2025, 20:46 UTC

Acquisizioni, Fusioni, Takeovers

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

22 mag 2025, 20:39 UTC

Utili

Tesla's Emissions Credits Are at Risk After Senate's California Vote -- Barrons.com

22 mag 2025, 20:36 UTC

Notizie principali

Antitrust Cops Say BlackRock, Other Fund Giants May Have Harmed Energy Competition -- 4th Update

22 mag 2025, 20:36 UTC

Notizie principali
Utili

Workday Logs Higher 1Q Revenue, Backs Outlook; Initiates $1B Buyback Program

22 mag 2025, 20:32 UTC

Notizie principali
Utili

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22 mag 2025, 20:27 UTC

Notizie principali

Trump's 'Big, Beautiful Bill' Heads to Senate, Where New Fights Loom -- WSJ

22 mag 2025, 20:20 UTC

Notizie principali

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22 mag 2025, 20:17 UTC

Notizie principali

The Deficit Is Unsettling Bond Traders. Here's How That Affects the Economy. -- 2nd Update

22 mag 2025, 20:16 UTC

Utili

Intchains Group 1Q Rev $18.2M >ICG

22 mag 2025, 20:15 UTC

Notizie principali

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22 mag 2025, 20:08 UTC

Notizie principali
Utili

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22 mag 2025, 20:05 UTC

Notizie principali

Intuit Seeing Stable Environment for Consumers, Businesses While Tariffs Play Out

22 mag 2025, 20:04 UTC

Utili

Workday Sees FY26 Subscription Revenue $8.8B >WDAY

22 mag 2025, 20:04 UTC

Utili

Workday Sees 2Q Subscription Revenue $2.16B >WDAY

22 mag 2025, 20:01 UTC

Utili

Intuit Sees FY25 EPS $13.19-EPS $12.24 >INTU

22 mag 2025, 20:01 UTC

Utili

Workday 1Q Net $68M >WDAY

22 mag 2025, 20:01 UTC

Utili

Workday 1Q EPS 25c >WDAY

22 mag 2025, 20:01 UTC

Utili

Workday 1Q Adj EPS $2.23 >WDAY

Confronto tra pari

Modifica del prezzo

Roivant Sciences Ltd Previsione

Obiettivo di Prezzo

By TipRanks

64.99% in crescita

Previsioni per 12 mesi

Media 18 USD  64.99%

Alto 18 USD

Basso 18 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Roivant Sciences Ltd - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

5 ratings

5

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

11 / 11.18Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

174 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.